Daiichi Sankyo Company, Limited (TYO: 4568)
Japan
· Delayed Price · Currency is JPY | Market Cap | 8.30T |
| Revenue (ttm) | 1.76T |
| Net Income (ttm) | 250.40B |
| Shares Out | 1.88B |
| EPS (ttm) | 130.80 |
| PE Ratio | 33.77 |
| Forward PE | 38.13 |
| Dividend | 60.00 (1.47%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 13,541,200 |
| Average Volume | 4,069,070 |
| Open | 4,300.00 |
| Previous Close | 4,081.00 |
| Day's Range | 4,288.00 - 4,475.00 |
| 52-Week Range | 4,015.00 - 6,257.00 |
| Beta | 0.27 |
| RSI | 30.60 |
| Earnings Date | Jan 31, 2025 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhi... [Read more]
Financial Performance
In 2023, Daiichi Sankyo Company's revenue was 1.60 trillion, an increase of 25.28% compared to the previous year's 1.28 trillion. Earnings were 200.73 billion, an increase of 83.84%.
Financial StatementsNews
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
First approval in the US for AstraZeneca and Daiichi Sankyo's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy DATROWAY is ...
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
First approval in the U.S. for Daiichi Sankyo and AstraZeneca's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy Second ...
AstraZeneca, Daiichi Sankyo antibody-drug conjugate Dato-DXd gains FDA nod
AstraZeneca (AZN) and Daiichi Sankyo's ADC Drug Gains Priority Review by FDA
AstraZeneca (AZN) and Daiichi Sankyo's ADC Drug Gains Priority Review by FDA
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumo...
High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower
Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for risk-tolerant investors. See more here.
Daiichi Sankyo gets Japanese approval for Datroway
Daiichi Sankyo (DSKYF) stock slid 10% after the drugmaker announced it had received approval in Japan for its DXd ADC Datroway for the treatment of HR+, HER2- breast cancer.
Astra, Daiichi Withdraw EU Application for Lung Cancer Drug
AstraZeneca Plc and Daiichi Sankyo Co. have voluntarily withdrawn an application for a lung cancer treatment in the European Union in a blow for the experimental drug.
England Pricing Talks Fail on Astra, Daiichi Breast Cancer Drug
AstraZeneca Plc and Daiichi Sankyo Co Ltd have once again failed to reach an agreement with England’s drug pricing regulator on the cost of a breast cancer medicine.
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and real-world data from seven abstracts for TURALIO® (pexidartinib) at the Connective Tissue Onco...
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo (TSE:4568) and AstraZeneca (NASDAQ: AZN) have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU ® (fam-trastuzumab deruxtecan-nxk...
Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ETCompany ParticipantsHiroyuki Okuzawa -...
Daiichi Sankyo COO: Partnerships with Merck & AstraZeneca going very well
Daiichi Sankyo's chief operating officer, Hiroyuki Okuzawa speaks about the company's drug pipeline and alliances with global pharmaceutical firms.
Daiichi Sankyo Company, Limited 2024 Q2 - Results - Earnings Call Presentation
Daiichi Sankyo Eyes Newer Cancer Drugs to Stave off Rivals
Drugmaker Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the US.
Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast ...
Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast Cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
Based on DESTINY-Breast06 Phase III trial which demonstrated a statistically significant and clinically meaningful progression-free survival benefit for ENHERTU If approved, AstraZeneca and Daiichi Sa...
AstraZeneca antibody drug candidate fails to meet overall survival goal in breast cancer
AstraZeneca and Daiichi Sankyo face setback as breast cancer drug fails to show significant overall survival benefit in final analysis. Read more here.
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Survival results for Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan in TROPION-Breast01 did not achieve statistical significance versus chemotherapy Trial previously met the dual primary endp...
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
Daiichi Sankyo's (DSNKY) ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial as a second-line therapy. Read more here.
Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
Daiichi Sankyo and AstraZeneca's ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12 Largest prospective trial of...
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases.
AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the British drugmaker’s experimental lung cancer medicine with partner Daiichi Sa...